Study guide
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders
Key Takeaways Explain This Topic AI
CKD is staged by eGFR (G1 to G5) and albuminuria (A1 to A3); drug doses follow the CrCl or eGFR named in the product monograph.
ACE inhibitors or ARBs for albuminuria, SGLT2 inhibitors started at eGFR 20 or more, finerenone in type 2 diabetes, and statins slow CKD progression or reduce cardiovascular risk.
Sick-day rules (SADMANS) temporarily hold sulfonylureas, ACE inhibitors, diuretics, metformin, ARBs, NSAIDs and SGLT2 inhibitors during dehydrating illness.
Phosphate binders such as calcium carbonate are taken with meals, and ESA therapy for CKD anemia should not target a hemoglobin of 130 g/L or more.
Hyperkalemia with ECG changes is treated first with IV calcium gluconate, then insulin with dextrose and salbutamol, then potassium removal.
Last updated: October 2026
Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders
Kidney function affects dosing for a large share of the drugs pharmacists dispense. CKD also brings its own pharmacotherapy: slowing progression, and managing anemia, mineral and bone disorder, and potassium. PEBC sample cases include a patient with CKD whose rising phosphate and potassium must be managed.
1. Staging CKD (KDIGO)
CKD is kidney damage or an eGFR below 60 mL/min/1.73 m² for more than 3 months. It is staged by GFR category and albuminuria category , because both predict risk:
- GFR category eGFR (mL/min/1.73 m²)
- G1 ≥ 90
- G2 60–89
- G3a 45–59
- G3b 30–44
- G4 15–29
- G5 < 15 (kidney failure)
- Albuminuria category Urine albumin-to-creatinine ratio (mg/mmol)
- A1 < 3
- A2 3–30
- A3 > 30
Use eGFR to stage disease. Use the CrCl or eGFR named in the product monograph for drug dosing; the PEBC formula sheet gives the Cockcroft-Gault equation (section 3.3).
2. Slowing CKD Progression
Blood pressure control: systolic below 130 mmHg (Hypertension Canada 2025) if tolerated.
ACE inhibitor or ARB (not both), titrated to the maximum tolerated dose in patients with albuminuria. A creatinine rise of up to about 30% after starting is expected.
SGLT2 inhibitors (dapagliflozin, empagliflozin) slow eGFR decline and reduce kidney failure and cardiovascular events in CKD with or without diabetes , especially when albuminuria is present. They are started at an eGFR of 20 or above and continued until dialysis. Their glucose-lowering effect fades at low eGFR, but kidney protection does not.
Finerenone , a non-steroidal mineralocorticoid receptor antagonist, for type 2 diabetes with albuminuric CKD already on a RAS inhibitor, when potassium is normal.
Statin for most adults 50 years and older with CKD who are not on dialysis.
Avoid nephrotoxins: NSAIDs, unnecessary contrast, and aminoglycosides where possible.
Important
Sick-day guidance ("SADMANS"): during vomiting, diarrhea or poor fluid intake, patients temporarily hold S ulfonylureas, A CE inhibitors, D iuretics, M etformin, A RBs, N SAIDs and S GLT2 inhibitors. They restart 24 to 48 hours after eating and drinking normally. This reduces the risk of acute kidney injury, lactic acidosis, euglycemic ketoacidosis and hypoglycemia.
- 3. Complications of CKD
- Anemia
Check iron status first: ferritin and transferrin saturation. Correct deficiency (oral, or IV in advanced CKD and dialysis) before starting erythropoiesis-stimulating agents (epoetin alfa, darbepoetin).
ESA Hb target: about 100 to 115 g/L. Do not target 130 g/L or more ; aiming that high increased stroke, thrombosis and cardiovascular events in trials. ESAs can also raise blood pressure.
Mineral and Bone Disorder
Mechanism: falling phosphate excretion and reduced vitamin D activation lead to high phosphate, low calcium and secondary hyperparathyroidism .
Dietary phosphate restriction comes first.
Phosphate binders are taken with meals , so they bind dietary phosphate:
calcium carbonate (inexpensive and first-line in many patients; avoid in hypercalcemia or vascular calcification);
sevelamer (calcium-free; GI adverse effects);
lanthanum .
Aluminum binders are avoided long term (toxicity), and magnesium-based antacids are avoided in CKD.
Separate binders from levothyroxine, fluoroquinolones, tetracyclines and iron.
Active vitamin D (calcitriol, alfacalcidol) and cinacalcet treat secondary hyperparathyroidism.
4. Hyperkalemia
Situation Management
ECG changes or K⁺ about 6.5 mmol/L or higher (emergency) 1) IV calcium gluconate to stabilize the heart membrane: acts within minutes, does not lower potassium. 2) Shift potassium into cells: regular insulin IV with dextrose, and nebulized salbutamol. 3) Remove potassium: binders, loop diuretics, or dialysis
Mild, asymptomatic, no ECG change (about 5.5 to 6.0 mmol/L) Review diet and potassium-raising drugs, then add a potassium binder
Drugs that raise potassium: ACE inhibitors, ARBs, MRAs, potassium supplements and salt substitutes (KCl) , trimethoprim, NSAIDs, heparin, and calcineurin inhibitors.
Potassium binders:
Sodium polystyrene sulfonate: slow onset. Separate other oral drugs by at least 3 hours. Rare intestinal necrosis risk.
Patiromer and sodium zirconium cyclosilicate: allow many patients to continue renin-angiotensin blockers.
PEBC sample items choose sodium polystyrene sulfonate for asymptomatic mild hyperkalemia in CKD.
5. Acute Kidney Injury (AKI) and Other Electrolytes
Pre-renal AKI: dehydration, heart failure, and the "triple whammy" of an ACE inhibitor or ARB plus a diuretic plus an NSAID.
Intrinsic AKI: aminoglycosides, vancomycin (higher trough levels), IV contrast, cisplatin, and drug-induced interstitial nephritis (PPIs, beta-lactams, NSAIDs).
Post-renal AKI: urinary retention, often from anticholinergics or decongestants in men with BPH.
Hyponatremia:
Common drug causes: thiazides, SSRIs and SNRIs, carbamazepine and oxcarbazepine, desmopressin.
Correct chronic hyponatremia slowly , generally no more than 8 to 10 mmol/L in 24 hours , to avoid osmotic demyelination.
Hypokalemia from loop or thiazide diuretics: replace potassium chloride, and correct magnesium , or potassium will not normalize.
Dosing Pearls in Reduced Kidney Function
Metformin: reduce the dose at an eGFR of 30 to 45; stop below 30.
Nitrofurantoin: limited by renal function (section 11.2).
Gabapentin and pregabalin: reduce the dose (sedation and falls).
DOACs and enoxaparin: adjust by CrCl.
Avoid in severe CKD: meperidine, codeine and morphine (metabolite accumulation), and phosphate enemas, magnesium laxatives and antacids (phosphate or magnesium toxicity).